TickerFacts.

Calidi Biotherapeutics, Inc. (CLDI): Long-Term Debt

Annual figures by period end, from SEC filings.

$600.0K
As of 2025-12-31
$600.0K
As of 2026-06-30
$2.06M2023-12-31: $2.06M2024-12-31: $600.0K2025-12-31: $600.0K$600.0K
2023-12-31 Long-Term Debt (USD) 2025-12-31
Period endedLong-Term DebtChange YoYSource filing
2025-12-31$600.0K0.0%2026-03-27, Balance as of period end
2024-12-31$600.0K-70.9%2026-03-27, Balance as of period end
2023-12-31$2.06Mn/a2025-03-31, Balance as of period end

Long-Term Debt at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedLong-Term DebtChange YoY
Calidi Biotherapeutics, Inc. (CLDI)2025-12-31$600.0K0.0%
AIM ImmunoTech Inc. (AIM)2025-12-31$4.48M+59.5%
Eloxx Pharmaceuticals, Inc. (ELOX)2025-12-31$1.00Mn/a
Inmune Bio, Inc. (INMB)2024-12-31$15.00Mn/a
Fennec Pharmaceuticals Inc. (FENC)2024-12-31$19.34M-37.5%
Quince Therapeutics, Inc. (QNCX)2025-12-31$0-100.0%
Humacyte, Inc. (HUMA)2025-12-31$35.44Mn/a
Acumen Pharmaceuticals, Inc. (ABOS)2025-12-31$22.40M-23.9%
Editas Medicine, Inc. (EDIT)2024-12-31$57.43Mn/a

Compare CLDI, AIM, ELOX, INMB side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗